Brossard, Patrick
Laveille, Christian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis
https://doi.org/10.1007/s40744-024-00669-y
Documents that mention this clinical trial
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis
https://doi.org/10.1007/s40744-024-00669-y
Efficacy and safety of emapalumab in macrophage activation syndrome
https://doi.org/10.1136/ard-2022-223739
AB1481 EMERALD STUDY DESIGN: A TWO-COHORT, OPEN-LABEL, SINGLE-ARM STUDY OF EMAPALUMAB, AN ANTI–INTERFERON-Γ (IFNΓ) MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN RHEUMATIC DISEASES
https://doi.org/10.1136/annrheumdis-2023-eular.2825
Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome
https://doi.org/10.1136/annrheumdis-2020-217470
OP0290 EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)
https://doi.org/10.1136/annrheumdis-2020-eular.3169
OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS
https://doi.org/10.1136/annrheumdis-2022-eular.803
OP0204 EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)
https://doi.org/10.1136/annrheumdis-2019-eular.3341
Documents that mention this clinical trial
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis
https://doi.org/10.1007/s40744-024-00669-y
Efficacy and safety of emapalumab in macrophage activation syndrome
https://doi.org/10.1136/ard-2022-223739
OP0193 EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS
https://doi.org/10.1136/annrheumdis-2022-eular.803
Funding for this research was provided by:
Swedish Orphan Biovitrum
Article History
Received: 1 February 2024
Accepted: 22 March 2024
First Online: 25 April 2024
Declarations
:
: Patrick Brossard is an employee of Sobi. Christian Laveille is a paid consultant to Sobi.
: All studies were conducted in accordance with the principles set forth in the Declaration of Helsinki, the Guidelines of the ICH on Good Clinical Practice (GCP) (CPMP/ICH/135/95), European Union Directive 95/46/EC and other applicable regulatory requirements. Independent ethical committee review and approval was obtained prior to initiating the studies and all patients (or their legal guardians) provided written informed consent prior to enrollment.